Irritable Bowel Syndrome News

A prototype point-of-care platform technology based on fecal gas analysis was effective for positively diagnosing irritable bowel syndrome and active inflammatory bowel disease in a recent study.

Mutations in the gene encoding the enzyme sucrase-isomaltase, responsible for the digestion of small carbohydrates from sugars and starches called disaccharides, are associated with an increased risk for irritable bowel syndrome, according to recent study data.

LAS VEGAS — Tenapanor at a dose of 50 mg twice per day significantly improved global endpoints in constipation-predominant irritable bowel syndrome, according to phase 2b trial data presented at ACG 2016.

About half of patients with diarrhea-predominant irritable bowel syndrome had adequate symptom relief on either a low FODMAP diet or traditional IBS dietary advice, according to results from a randomized controlled trial.

Gut microbiota profiles in stool samples of patients with irritable bowel syndrome predicted response to a low FODMAP diet, according to research presented at UEG Week 2016.

LAS VEGAS — In this exclusive video, Nicholas J. Talley, MD, PhD, professor of medicine and pro vice-chancellor of global research at the University of Newcastle, Australia, discusses the David Sun Lecture, which he delivered at ACG 2016. This distinguished lecture focused on new developments in functional gut disorders.

LAS VEGAS — In this exclusive video from ACG 2016, William D. Chey, MD, professor of medicine, director of the GI Physiology Lab, and co-director of the Michigan Bowel Control Program at the University of Michigan, Ann Arbor, discusses the results of a phase 2b randomized controlled trial of tenapanor (Ardelyx), a small molecule that inhibits sodium reabsorption via the NHE3 receptor, in patients with constipation predominant irritable bowel syndrome.

LAS VEGAS — Lyrica may improve symptoms of irritable bowel syndrome, including overall symptoms, abdominal pain and potentially bloating and diarrhea, according to the results of a pilot randomized controlled trial presented at ACG 2016.

Allergan and SonarMD have partnered to develop clinical decision support and patient engagement tools to improve diagnosis and monitoring of patients with diarrhea-predominant irritable bowel syndrome, according to a press release.